Markers of Inflammation after Simvastatin in Ischemic Cortical Stroke "MISTICS"


Phase N/A Results

Trial Description

To study the safety and efficacy of Simvastatin in the acute phase of ischemic stroke.


  • Simvastatin Drug
    Intervention Desc: HMG-CoA reductase inhibitor; lowers cholesterol

Trial Design

Pilot, randomized, double-blind, multi-center clinical trial.

Patient Involvement

Patients were randomized to receive either Simvastatin (n=28) or placebo (n=28) 40mg until day 7 and 20mg until day 90.


Type Measure Time Frame Safety Issue
Primary Efficacy and neurological outcome at day 1, 3, 5, 7 and 90.